Quarry LP Buys 2,610 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Quarry LP raised its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 59.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,002 shares of the company’s stock after purchasing an additional 2,610 shares during the period. Quarry LP’s holdings in Health Catalyst were worth $45,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in HCAT. Nisa Investment Advisors LLC grew its holdings in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares in the last quarter. Perfromance Wealth Partners LLC purchased a new position in shares of Health Catalyst in the 2nd quarter worth $64,000. Mackenzie Financial Corp bought a new stake in shares of Health Catalyst in the 2nd quarter worth about $70,000. EntryPoint Capital LLC bought a new stake in shares of Health Catalyst in the 1st quarter worth about $98,000. Finally, Virtus Investment Advisers Inc. purchased a new stake in Health Catalyst during the first quarter valued at approximately $115,000. Institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on HCAT. Piper Sandler cut their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday. Stephens dropped their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Evercore ISI decreased their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Finally, JPMorgan Chase & Co. increased their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.42.

Insider Buying and Selling

In related news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,153 shares of company stock valued at $216,004. 2.70% of the stock is currently owned by corporate insiders.

Health Catalyst Stock Up 0.9 %

NASDAQ:HCAT opened at $7.70 on Friday. The stock’s fifty day moving average is $7.43 and its two-hundred day moving average is $6.90. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41. The stock has a market capitalization of $454.57 million, a price-to-earnings ratio of -4.16 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.21) EPS. On average, sell-side analysts expect that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.